20.04.2024 | IM - COMMENTARY
Treating colonic diverticula with rifaximin: a call to action
verfasst von:
Gabrio Bassotti
Erschienen in:
Internal and Emergency Medicine
Einloggen, um Zugang zu erhalten
Excerpt
Colonic diverticular disease (CDD) is the symptomatic form of a frequent condition encountered in the daily clinical practice, i.e. diverticulosis [
1]. The treatment of CDD is challenging for the caring physicians, including general practitioners (GP) and gastroenterologists (GE) and cyclic treatment with rifaximin is the most frequent drug used in this context [
2]. Although the available evidence indicates the safety and effectiveness of rifaximin in to treat symptomatic uncomplicated diverticular disease (SUDD), there are insufficient data regarding its use to prevent recurrent diverticulitis and the cost–benefit of long-term treatment [
3]. …